… RCTs 19, 22 focused on hospitalized patients with COVID-19; … of molnupiravir in treating
hospitalized patients. Second, although the effect of molnupiravir use on unvaccinated patients …

… that molnupiravir may only be effective in some subgroups of hospitalized patients; therefore…
In conclusion, our study supports the use of molnupiravir in non-hospitalized patients with …

… The authors found no effect of molnupiravir on their key outcome, hospitalization (RR 0.71;
95% CI 0.42–1.22), which is in agreement with our findings. The WHO living guideline group …

… as a treatment for hospitalized patients with COVID-19 … hospitalization and death among
non-hospitalized patients … patients requiring hospitalization could be hospitalized in our …

… non-hospitalized patients with COVID-19 who are at high risk of disease progression, the
currently recommended anti-viral agents, nirmatrelvir plus ritonavir, molnupiravir and remdesivir…

… between the molnupiravir and … hospitalization was lower in the molnupiravir group compared
with the control group (RR=0.67; p = 0.05, 95% CI = 0.45–0.99; I2 =53%), and molnupiravir …

… Hospital Authority to identify an unselected, territory-wide cohort of non-hospitalised patients
… We identified patients with COVID-19 who received either molnupiravir (800 mg twice daily …

… Molnupiravir is an oral prodrug of β-D-N4-hydroxycytidine, active … molnupiravir in patients
hospitalized with Covid-19. … efficacy of molnupiravir in the hospitalized participants studied: …

… the safety and efficacy of Molnupiravir in SARS-COV-2 infections. … hospitalization or death
in high-risk mild COVID-19 patients. Molnupiravir was also found to be well tolerated and safe …

… There are currently some differences in the research results of molnupiravir. This study
aimed to evaluate the efficacy and safety of molnupiravir in the treatment of COVID-19. …